Education
Poster Abstracts
Poster Abstracts
Resident Poster Presentations Sponsored by:
| Presenter | Abstract Title |
|---|---|
| Ariel Davis | A pilot study evaluating cytology, flow cytometry and PARR in sequential nodal samples from dogs receiving chemotherapy for lymphoma |
| Dansong Seo | Benign primary hepatic proliferative lesions in a captive population of Mississippi gopher frogs (Lithobates sevosus) |
| Kathryn Shaffert | Cell cycle inhibitors exhibit variable impacts on cellular proliferation in canine osteosarcoma cell lines independent of SETD2 mutations |
| Allison Valentijn | Fragment length of cell-free DNA can predict malignancy in canine pericardial effusion: Pilot study of 11 cases |
| Grace Wei-Qi Woo | Frunevetmab (Solensia®) with palliative-intent radiation therapy and meloxicam for feline bone-invasive oral squamous cell carcinoma: A pilot study |
| Saige Margolin | Investigation of the utility of DNA damage response gene expression to predict early treatment failure in canine osteosarcoma |
| Erin Paul-Stewart | Preclinical evaluation of a novel SHP-1 inhibitor in laboratory dogs |
| Rachel Hanford | Prophylactic metronidazole reduces clinically relevant diarrhea in dogs receiving doxorubicin chemotherapy: A prospective, randomized, double-blinded, placebo-controlled study |
| Samantha von Rueden | Proteomic investigation of liquid biomarkers for canine splenic hemangiosarcoma |
| Zachary Fawver | Regional and formulation-associated variability in Lomustine (CCNU) dosing, toxicity, and tolerability in dogs with cancer: A multi-institutional study |
| David Barry | Reticulocytosis with and without hematocrit decline following vinca alkaloid administration in cancer-bearing dogs |
| Pakawan Asawawongsawat | Validating somatostatin receptor expressions and druggability in canine insulinoma |
| Presenter | Abstract Title |
|---|---|
| Chloe Quin | A pilot study demonstrating the radiosensitizing effects of lapatinib in canine transitional cell carcinoma, hemangiosarcoma, and melanoma cell lines |
| Allison Naclerio | A retrospective analysis of chemotherapy adverse events in canine patients with ABCB1-Δ1 mutations |
| Seulgi Hwang | Association of circulating myeloid-derived suppressor cells with hematological indices, tumor-associated inflammation, and tumor progression in tumor-bearing dogs |
| Jaewoo Hong | Canicancer: Comprehensive somatic and germline mutation profiling for targeted therapy in canine malignancies |
| Timothy Fan | Characterizing systemic immune activation and identifying rational combination regimens with intratumoral cytokines for maximizing abscopal effects in metastatic sarcoma |
| Michelle Chu | Clinical concordance in veterinary practice: Measuring guideline compliance for preventive care in long-term canine cancer survivors |
| Myeongyeon Lee | Clinical response and outcome of repeated L-asparaginase-based chemotherapy in 10 dogs with cutaneous epitheliotropic lymphoma |
| Dana Connell | Clinical significance of serial Cancer Dx testing in dogs |
| Madison Toonder | Clinicopathologic features and outcomes of acute tumor lysis syndrome in dogs with lymphoma: A matched case-control study |
| Tiffany Martin | Combination of hypofractionated radiation therapy and Gilvetmab for the treatment of mast cell tumors in dogs |
| Guannan Wang | Comprehensive genomic profiling delineates clonal and independent multi-tumor disease in dogs to inform clinical decision-making |
| Abhikumar Patel | Deciphering the molecular landscape of vincristine response in canine transmissible venereal tumor through genome-wide RNA sequencing |
| Marc Brillantes | Development of an engineered canine anti-CD19 antibody for therapeutic depletion of B cells |
| Surya Vishnubhatt | Drug response prediction-guided treatment selection is associated with improved survival and remission in canine T-cell lymphoma |
| Mark Mamula | EGFR/HER2 immunotherapy in dogs with osteosarcoma, hemangiosarcoma and transitional cell carcinoma |
| Sara Cook | Establishing a preclinical patient derived xenograft (PDX) model for peripheral T cell lymphoma, not otherwise specified |
| Adriana Moraes | Expression of indoleamine 2,3-dioxygenase (IDO) and lymphocytic infiltrate in feline melanomas: a retrospective study |
| Ashley Estrada | Fecal microbiota profiling differentiates canine health from disease but reveals a shared dysbiosis across heterogeneous illnesses |
| Carlos Eduardo Fonseca-Alves | FZD5 single nucleotide variant as a novel urine-based diagnostic biomarker for canine prostatic carcinoma |
| Christopher Pinard | Generation of a research database using a commercial veterinary-specific ai pipeline: A proof-of-concept study |
| Tatianna Travieso | Genomic and transcriptomic characterization of canine B cell lymphoma subtypes defined by flow cytometry |
| Lucas Rodrigues | Genomic profiling reveals prognostically distinct molecular subtypes within canine cancers |
| Alison Masyr | Ghrelin and growth hormone secretagogue receptor (GHS-R) mRNA expression in canine exocrine and endocrine pancreatic tumors |
| Wenchuan Sun | IB-DNQ: AN NQO1-activated prodrug that induces immunogenic cell death and enhances immunotherapy in bladder cancer |
| Takumi Tsurata | In vitro effects of bortezomib on feline lymphoma cell lines |
| Sharadha Sakthikumar | Integrated multi-omic landscape of canine osteosarcoma, soft tissue sarcoma, and B-cell lymphoma reveals novel subtypes and therapeutic vulnerabilities |
| James Perry | Interim survival and safety of paclitaxel micellar in dogs with stage I-II splenic hemangiosarcoma after splenectomy |
| Nabeel Ahmad | Investigating procaspase-activating compound 1 (PAC-1) as a pharmacologic strategy to overcome immune checkpoint inhibitor resistance |
| Maureen Griffin | Investigation of the role of cystourethroscopy in canine urothelial carcinoma: An expanded multi-institutional cohort |
| Amy Treeful | Matrix and metadata-driven variance in baseline canine cfDNA: validating inputs for a machine learning risk stratification for DLBCL |
| Johanna Mettler | Metabolic glycan labeling enables cytokine-functionalized canine dendritic cells for cancer immunotherapy applications |
| Franco Portillo | Orthovoltage radiotherapy as salvage treatment for chemotherapy-refractory canine transmissible venereal tumor: Outcomes in an endemic, resource-limited setting |
| Kristen Couto | Paclitaxel micellar dose-escalation study in cats with spontaneous solid tumors |
| Isabelle Vanhaezebrouck | Personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) in companion animals: Workflow and preliminary results |
| Kim Selting | Phase 0 and 1 evaluation of daunomustine as a novel anticancer chemotherapeutic in normal dogs and dogs with chemotherapy naïve lymphoma |
| Jin-Hyuk Park | Primary tumor transcriptome signature is associated with locoregional lymphatic spread in canine mammary carcinoma |
| Xuan Pan | Prospective evaluation of Cancerk9, a multi-cancer cell-free DNA liquid biopsy assay, in dogs with naturally occurring cancers |
| Atsushi Maeda | PTBP1 as a therapeutic target in canine and human malignant melanoma: A comparative oncology study |
| Jin-Hyuk Park | Radiosensitizing effects of olaparib in canine melanoma cell lines in vitro and in vivo |
| Alan Fine | Rapid in-clinic canine lymphoma and leukemia immunophenotyping |
| Mai Miyazaki | Relationship between anti-L-asparaginase antibodies and clinical resistance to L-asparaginase in dogs with lymphoma |
| Mary Frye | Retrospective cost analysis of machine learning-guided chemotherapy selection in dogs with relapsed B-cell lymphoma, stratified by prediction-treatment concordance |
| Mattison McMillan | Retrospective evaluation of zoledronate vs zoledronate and carboplatin for treatment of canine appendicular osteosarcoma |
| Matias Tellado | Role of metronomic chemotherapy after palliative electrochemotherapy in non-resectable oral malignant tumors |
| Kathryn Vickery | Serial evaluation of chemotherapy response assessment using 18F-FDG PET/CT combined with flow cytometry and PARR in dogs with lymphoma: A pilot study |
| Matthew Berry | Serum-free culture generates distinct canine monocyte-derived dendritic cells for immunotherapy development |
| Molly McGuckin | Spatial analysis of the tumor microenvironment in naturally occurring canine diffuse large B-cell lymphoma |
| Rui Mizuno | Stage-specific survival benefit of adjunctive toceranib phosphate in canine nasal tumors treated with megavoltage radiation therapy: A retrospective study of 279 cases |
| Rebecca Pryor | Targeting RAS signaling to disrupt molecular programs that regulate vascular spatial organization in canine hemangiosarcoma |
| Joanne Tuohy | The first combination of histotripsy with intratumoral immunotherapy in pet dogs with osteosarcoma |
| Juan Vizcay | Tonsillar tumors in dogs treated with tonsillectomy and electrochemotherapy |
| Grace Walker | Ultima UG100 enables lower cost sequencing with comparable quality to element AVITI24 for canine cell-free DNA profiling |